BUY Gland Pharma Limited — Shrikant Chouhan, Kotak Securities
byShrikant Chouhan, Kotak SecuritiesHorizon: NA (inferred Swing (≤2wk))10 Sept 2026via NDTV Profit
Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.
AI Assessment
Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.
Past week's volume 1.6× the 30-day average
Technicals · volume·10 Sept · today
5 advisors have active short-term BUY calls on this stock, with 1 issued in the last 14 days
Advisor consensus · adjacent horizon·7 Sept · 3d ago
Block deal alert! Gland Pharma shares fall 3% as 1.2 crore shares change hands in 2 block deals; promoter Fosun likely seller
NewsEt-Markets·4 Sept · 6d ago
Gland Pharma shares: Promoter Fosun Pharma likely to divest 5% equity worth Rs 2,279 crore via block deal
NewsEt-Markets·3 Sept · 6d ago
Gland Pharma Block Deal: Fosun Pharma to sell 5% stake at ₹2,763/share
NewsCnbc-Tv18·3 Sept · 1w ago
Fosun Pharma sells 4.5% stake in Gland Pharma for Rs 2,121 crore
NewsHbl·5 Sept · 4d ago
Gland Pharma block deal: Fosun Pharma divests 99 lakh shares worth Rs 2,800 crore
NewsEt-Markets·4 Sept · 5d ago
Fosun Pharma sells 6% stake in Gland Pharma for ₹2,800 crore; three mutual funds pick up shares
NewsCnbc-Tv18·4 Sept · 6d ago
Block deal alert! Gland Pharma shares in focus as promoter Fosun to sell 5% stake for Rs 2,279 crore
NewsEt-Markets·4 Sept · 6d ago
Gland Pharma Promoter Likely To Sell 5% Stake Via Rs 2,279 Crore Block Deal
NewsNdtv-Profit·3 Sept · 1w ago
MACD below its signal line — bearish momentum
Technicals · macd·10 Sept · today
Gland Pharma shares fall after ₹2,100 crore block deal; Promoter likely seller
NewsCnbc-Tv18·4 Sept · 6d ago
Large trade alert! Gland Pharma shares fall 3% after 1.2 crore shares change hands in 2 block deals; promoter Fosun likely seller
NewsEt-Markets·4 Sept · 6d ago
Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.